Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.
Apolipoprotein C-III
Biomarkers
Diabetes
Glucose metabolism
Lipoproteins
Observational study
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
22
06
2018
accepted:
07
02
2019
pubmed:
6
4
2019
medline:
14
1
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Apolipoprotein C-III (apoC-III) is a small proinflammatory protein that may play a key role in diabetes pathophysiology. However, prior observational studies have been limited to predominantly white populations, and the biological links between apoC-III and diabetes, particularly the role of apoC-III on specific lipoprotein particles, are not yet well understood. We therefore investigated associations of total apoC-III and apoC-III-defined lipoprotein subspecies with incident diabetes and glucose metabolism measures in a multi-ethnic cohort. For the current analyses, baseline (2000-2002) plasma total apoC-III and apolipoprotein A-I concentrations of HDL containing or lacking apoC-III were newly measured via sandwich ELISA in 4579 participants from the Multi-Ethnic Study of Atherosclerosis. Multivariable Cox regression was used to examine associations of apolipoproteins with incident diabetes until early 2012 (567 cases), and linear mixed models were used to estimate associations with longitudinally assessed continuous measures of glucose metabolism. Similar exploratory analyses of plasma apolipoprotein B concentrations of LDL and VLDL containing or lacking apoC-III were performed in a subset of participants (LDL, n = 1545; VLDL, n = 1526). In the overall population, elevated total apoC-III concentrations were associated with a higher rate of diabetes (top vs bottom quintile, HR 1.88; 95% CI 1.42, 2.47; p Our findings in a multi-ethnic population support the involvement of apoC-III in the development of diabetes, potentially through its association with circulating triacylglycerols. The presence of apoC-III on HDL also diminished the protective association of HDL with incident diabetes. Further investigation of apoC-III and apoC-III-defined HDL subspecies may inform the development of novel diabetes treatment and prevention strategies.
Identifiants
pubmed: 30949716
doi: 10.1007/s00125-019-4847-8
pii: 10.1007/s00125-019-4847-8
doi:
Substances chimiques
Apolipoprotein A-I
0
Apolipoprotein C-III
0
Lipoproteins
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
981-992Subventions
Organisme : NHLBI NIH HHS
ID : R21 HL091217
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK 007703
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL071739
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000040
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Références
American Diabetes Association (2017) 2. Classification and diagnosis of diabetes. Diabetes Care 40(Supplement 1):S11–S24. https://doi.org/10.2337/dc17-S005
doi: 10.2337/dc17-S005
Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA (2012) The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 8(4):237–245. https://doi.org/10.1038/nrendo.2011.235
doi: 10.1038/nrendo.2011.235
pubmed: 22271188
Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5(3):150–159. https://doi.org/10.1038/ncpendmet1066
doi: 10.1038/ncpendmet1066
pubmed: 19229235
Wyler von Ballmoos MC, Haring B, Sacks FM (2015) The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis. J Clin Lipidol 9(4):498–510. https://doi.org/10.1016/j.jacl.2015.05.002
doi: 10.1016/j.jacl.2015.05.002
pubmed: 26228667
Zheng C, Khoo C, Furtado J, Sacks FM (2010) Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121(15):1722–1734. https://doi.org/10.1161/CIRCULATIONAHA.109.875807
doi: 10.1161/CIRCULATIONAHA.109.875807
pubmed: 20368524
pmcid: 3153990
Sacks FM (2015) The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol 26(1):56–63. https://doi.org/10.1097/MOL.0000000000000146
doi: 10.1097/MOL.0000000000000146
pubmed: 25551803
pmcid: 4371603
Brown WV, Baginsky ML (1972) Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 46(2):375–382. https://doi.org/10.1016/S0006-291X(72)80149-9
doi: 10.1016/S0006-291X(72)80149-9
pubmed: 5057882
Liu H, Talmud PJ, Lins L et al (2000) Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase. Biochemistry 39(31):9201–9212. https://doi.org/10.1021/bi0009441
doi: 10.1021/bi0009441
pubmed: 10924113
Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75(2):384–390. https://doi.org/10.1172/JCI111711
doi: 10.1172/JCI111711
pubmed: 3973011
pmcid: 423500
Lee HY, Birkenfeld AL, Jornayvaz FR et al (2011) Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54(5):1650–1660. https://doi.org/10.1002/hep.24571
doi: 10.1002/hep.24571
pubmed: 21793029
Avall K, Ali Y, Leibiger IB et al (2015) Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes. Proc Natl Acad Sci U S A 112(20):E2611–E2619. https://doi.org/10.1073/pnas.1423849112
doi: 10.1073/pnas.1423849112
pubmed: 25941406
pmcid: 4443338
Holmberg R, Refai E, Hoog A et al (2011) Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci U S A 108(26):10685–10689. https://doi.org/10.1073/pnas.1019553108
doi: 10.1073/pnas.1019553108
pubmed: 21670290
pmcid: 3127896
Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM (2006) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114(7):681–687. https://doi.org/10.1161/CIRCULATIONAHA.106.622514
doi: 10.1161/CIRCULATIONAHA.106.622514
pubmed: 16894036
Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM (2006) Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113(5):691–700. https://doi.org/10.1161/CIRCULATIONAHA.105.591743
doi: 10.1161/CIRCULATIONAHA.105.591743
pubmed: 16461842
Aroner SA, Yang M, Li J et al (2017) Apolipoprotein C-III and high-density lipoprotein subspecies defined by apolipoprotein C-III in relation to diabetes risk. Am J Epidemiol 186(6):736–744. https://doi.org/10.1093/aje/kwx143
doi: 10.1093/aje/kwx143
pubmed: 28520887
Onat A, Hergenc G, Ayhan E et al (2009) Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med 26(10):981–988. https://doi.org/10.1111/j.1464-5491.2009.02814.x
doi: 10.1111/j.1464-5491.2009.02814.x
pubmed: 19900229
Jensen MK, Aroner SA, Mukamal KJ et al (2017) HDL subspecies defined by presence of apolipoprotein C-III and incident coronary heart disease in four cohorts. Circulation 137:1364–1373
doi: 10.1161/CIRCULATIONAHA.117.031276
pubmed: 29162611
pmcid: 5871573
Aroner SA, Koch M, Mukamal KJ et al (2018) High-density lipoprotein subspecies defined by apolipoprotein C-III and subclinical atherosclerosis measures: MESA (the Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc 7:e007824
doi: 10.1161/JAHA.117.007824
pubmed: 29540426
pmcid: 5907551
Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM (2011) Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 124(19):2065–2072. https://doi.org/10.1161/CIRCULATIONAHA.111.056986
doi: 10.1161/CIRCULATIONAHA.111.056986
pubmed: 21986282
pmcid: 3244212
Rutti S, Ehses JA, Sibler RA et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic β-cells. Endocrinology 150(10):4521–4530. https://doi.org/10.1210/en.2009-0252
doi: 10.1210/en.2009-0252
pubmed: 19628574
Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM (2010) Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 59(5):1153–1160. https://doi.org/10.2337/db09-1114
doi: 10.2337/db09-1114
pubmed: 20185808
pmcid: 2857895
Mackey RH, Mora S, Bertoni AG et al (2015) Lipoprotein particles and incident type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis. Diabetes Care 38(4):628–636. https://doi.org/10.2337/dc14-0645
doi: 10.2337/dc14-0645
pubmed: 25592196
pmcid: 4370328
Bild DE, Bluemke DA, Burke GL et al (2002) Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 156(9):871–881. https://doi.org/10.1093/aje/kwf113
doi: 10.1093/aje/kwf113
pubmed: 12397006
McAuley KA, Williams SM, Mann JI et al (2001) Diagnosing insulin resistance in the general population. Diabetes Care 24(3):460–464. https://doi.org/10.2337/diacare.24.3.460
doi: 10.2337/diacare.24.3.460
pubmed: 11289468
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26(Suppl 1):S5–S20
Petersen L, Sorensen TI, Andersen PK (2003) Comparison of case-cohort estimators based on data on premature death of adult adoptees. Stat Med 22(24):3795–3803. https://doi.org/10.1002/sim.1672
doi: 10.1002/sim.1672
pubmed: 14673939
Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, Chichester
Kohan AB (2015) Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 22(2):119–125. https://doi.org/10.1097/MED.0000000000000136
doi: 10.1097/MED.0000000000000136
pubmed: 25692924
pmcid: 4524519
Grundy SM, Brewer HB Jr, Cleeman JI et al (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109(3):433–438. https://doi.org/10.1161/01.CIR.0000111245.75752.C6
doi: 10.1161/01.CIR.0000111245.75752.C6
pubmed: 14744958
Qin W, Sundaram M, Wang Y et al (2011) Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem 286(31):27769–27780. https://doi.org/10.1074/jbc.M110.203679
doi: 10.1074/jbc.M110.203679
pubmed: 21676879
pmcid: 3149367
Sundaram M, Zhong S, Bou Khalil M et al (2010) Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 51(1):150–161. https://doi.org/10.1194/jlr.M900346-JLR200
doi: 10.1194/jlr.M900346-JLR200
pubmed: 19622837
pmcid: 2789775
Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371(1):32–41. https://doi.org/10.1056/NEJMoa1308027
doi: 10.1056/NEJMoa1308027
pubmed: 24941082
Peter A, Kantartzis K, Machicao F et al (2012) Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int J Obes 36(6):774–782. https://doi.org/10.1038/ijo.2011.154
doi: 10.1038/ijo.2011.154
Petersen KF, Dufour S, Hariri A et al (2010) Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 362(12):1082–1089. https://doi.org/10.1056/NEJMoa0907295
doi: 10.1056/NEJMoa0907295
pubmed: 20335584
pmcid: 2976042
Pollin TI, Damcott CM, Shen H et al (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322(5908):1702–1705. https://doi.org/10.1126/science.1161524
doi: 10.1126/science.1161524
pubmed: 19074352
pmcid: 2673993
TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, Auer PL, Reiner AP (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371:22–31
Juntti-Berggren L, Refai E, Appelskog I et al (2004) Apolipoprotein CIII promotes Ca
doi: 10.1073/pnas.0403551101
pubmed: 15210953
pmcid: 454169
Jensen MK, Rimm EB, Furtado JD, Sacks FM (2012) Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc 1:e000232
doi: 10.1161/JAHA.111.000232
Abbasi A, Corpeleijn E, Gansevoort RT et al (2013) Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study. J Clin Endocrinol Metab 98(8):E1352–E1359. https://doi.org/10.1210/jc.2013-1680
doi: 10.1210/jc.2013-1680
pubmed: 23690306
Haase CL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R (2015) HDL cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes 64(9):3328–3333. https://doi.org/10.2337/db14-1603
doi: 10.2337/db14-1603
pubmed: 25972569
Njolstad I, Arnesen E, Lund-Larsen PG (1998) Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark study. Am J Epidemiol 147(1):49–58. https://doi.org/10.1093/oxfordjournals.aje.a009366
doi: 10.1093/oxfordjournals.aje.a009366
pubmed: 9440398
von Eckardstein A, Schulte H, Assmann G (2000) Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 85(9):3101–3108. https://doi.org/10.1210/jcem.85.9.6773
doi: 10.1210/jcem.85.9.6773
Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring study. Arch Intern Med 167(10):1068–1074. https://doi.org/10.1001/archinte.167.10.1068
doi: 10.1001/archinte.167.10.1068
pubmed: 17533210
Sparks JD, Sparks CE, Adeli K (2012) Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 32(9):2104–2112. https://doi.org/10.1161/ATVBAHA.111.241463
doi: 10.1161/ATVBAHA.111.241463
pubmed: 22796579
Roehrich ME, Mooser V, Lenain V et al (2003) Insulin-secreting β-cell dysfunction induced by human lipoproteins. J Biol Chem 278(20):18368–18375. https://doi.org/10.1074/jbc.M300102200
doi: 10.1074/jbc.M300102200
pubmed: 12594227
Lee SJ, Campos H, Moye LA, Sacks FM (2003) LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 23(5):853–858. https://doi.org/10.1161/01.ATV.0000066131.01313.EB
doi: 10.1161/01.ATV.0000066131.01313.EB
pubmed: 12637336
Havel RJ (1989) Biology of cholesterol, lipoproteins and atherosclerosis. Clin Exp Hypertens A 11(5-6):887–900. https://doi.org/10.3109/10641968909035380
doi: 10.3109/10641968909035380
pubmed: 2676261
Lee SJ, Moye LA, Campos H, Williams GH, Sacks FM (2003) Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 167(2):293–302. https://doi.org/10.1016/S0021-9150(03)00007-8
doi: 10.1016/S0021-9150(03)00007-8
pubmed: 12818412
Ishibashi S, Yamada N, Shimano H, Takaku F, Akanuma Y, Murase T (1989) Composition of very-low-density lipoproteins in non-insulin-dependent diabetes mellitus. Clin Chem 35(5):808–812
pubmed: 2720974